# What the FDA's Geref records say about its former indications

- Article ID: research-340
- Product: Sermorelin (sermorelin-631, sermorelin-485, sermorelin-633)
- Canonical page: https://heritagebiolabs.com/research-library/articles/340-what-the-fda-s-geref-records-say-about-its-former-indications
- Product collection: https://heritagebiolabs.com/research-library/products/sermorelin
- Product page: https://heritagebiolabs.com/product/sermorelin-631
- Product page: https://heritagebiolabs.com/product/sermorelin-485
- Product page: https://heritagebiolabs.com/product/sermorelin-633
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1996, 2013

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short chains of amino acids connected by peptide bonds are called peptides. Some can act on a pituitary receptor and prompt a hormone release. Sermorelin is a synthetic 29-residue fragment of human growth hormone–releasing hormone, with an amidated end. The history of Geref, a U.S. sermorelin acetate product, shows how a diagnostic approval and a treatment approval can address separate questions. [1, 2]

The FDA approved one Geref presentation in 1990 for evaluating whether the pituitary gland could release growth hormone (GH). That use measured a short response to a stimulus. The agency approved another presentation in 1997 for treating children with growth failure from idiopathic growth hormone deficiency. Idiopathic means that a definite cause has not been identified. The treatment indication concerned growth over time in children with a defined condition. [1]

The manufacturer notified the FDA in 2008 that the products were being discontinued and requested withdrawal of the approvals. The agency withdrew the approvals effective in 2009. In a 2013 Federal Register notice, the FDA determined that the specified products had been withdrawn from sale for reasons other than safety or effectiveness. The notice concerned those historical products and the reason they were withdrawn. It did not restore their approvals or evaluate a new formulation or indication. [1]

The older official record is the direct source for those regulatory events. A product's name, formulation, intended use and current regulatory status each matter when reading research or a label. An experiment examining hormone response or growth in a specific population supplies evidence about that experiment. It does not extend the historical approvals to unrelated uses. [1, 2]

## Sources

1. U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register (publication 2013-03-04). <https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm>
2. Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Journal of Clinical Endocrinology & Metabolism (publication 1996-03). <https://pubmed.ncbi.nlm.nih.gov/8772599/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 068 - Semax and Sermorelin.docx; article 340; content SHA-256 61f067bd562b56e8f3160e9314de1e7eb3cddaa851f4defd0182958154a4f1fa.
